Skip to content

Strive

US · ASST #2516 by market cap Listed 2023
14.51 -2.10 -12.64%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail
  • Asset Management is the largest reported line at 57.83% of revenue, across 3 reported segments.
  • Medical Device follows at 42.03%, so the top line still matters most but isn’t the whole story.

Revenue annual, last 3 years

Margins

Income statement

Line item 2023 2024 2025
Revenue 2.45M3.65M--
Gross profit -10.27M-10.35M--
Selling & admin expenses 7.65M12.11M--
Research & development ------
Operating profit -18.02M-22.65M--
Pretax profit -16.91M-21.58M--
Tax 00--
Net profit -16.91M-21.58M--
Basic EPS -147-188--
Diluted EPS -147.10-187.71--

Balance sheet

Line item 2023 2024 2025
Total current assets 16.16M23.76M71.78M
Cash & ST investments 15.65M22.91M67.50M
Inventory ------
Total assets 20.19M28.20M745.53M
Total current liabilities 1.52M3.34M10.78M
Short-term debt 261.19K----
Long-term debt ------
Total liabilities 4,136,412.004,855,000.0014,289,000.00
Total equity 16.06M23.34M731.24M
Retained earnings -27.57M-49.15M-474.05M

Cash flow

Line item 2023 2024 2025
Operating cash flow -16.42M-21.60M--
Depreciation & amortization 98.33K192.00K--
Free cash flow -17.39M-21.62M--
Dividends paid --0--
Stock buybacks / issuance --0--
Ending cash balance 2.09M6.16M--

Returns & efficiency

Line item 2023 2024 2025
ROE % ------
ROA % -83.74-89.19--
ROIC % ------
5-year avg ROE % ------
EBIT margin % -735.67-620.64--
FCF / sales % ------
Current ratio 10.667.126.66
Quick ratio 10.336.866.26
Debt / assets 14.275.380.47
LT debt / equity ----0.60
Interest coverage ------
Revenue CAGR (3Y) % ------
Net income CAGR (3Y) % ------
FCF CAGR (3Y) % ------

Revenue breakdown most recent period

Business

Asset Management57.83%
Medical Device42.03%
Corporate & Other0.15%

Quote time 2026-11-20 19:59:09 · For reference only, not investment advice and not tailored to your situation.

Strive discussion 0 comments

Add a comment